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Abstract
The growing population of left ventricular assist device (LVAD)-supported patients increases the probability of an LVAD- sup-
ported patient hospitalized in the internal or surgical wards with certain expected device related, and patient-device interac-
tion complication as well as with any other comorbidities requiring hospitalization. In this third part of the trilogy on the
management of LVAD-supported patients for the non-LVAD specialist healthcare provider, definitions and structured approach
to the hospitalized LVAD-supported patient are presented including blood pressure assessment, medical therapy of the LVAD
supported patient, and challenges related to anaesthesia and non-cardiac surgical interventions. Finally, important aspects to
consider when discharging an LVAD patient home and palliative and end-of-life approaches are described.
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In the internal medicine ward
Blood pressure management in LVAD patients
The haemodynamics and blood flow patterns of the left ven-
tricular assist device (LVAD) supported patients are unique to
the valve-less, continuous flow generated by the pump.
Blood flow through the pump is inversely related to pump
head pressure gradient [aortic pressure—left ventricular
(LV) pressure]. In every heart beat the flow through the pump
is increased on systole and decreased on diastole. The re-
duced native LV contractility of LVAD patients and the
unloading of the LV by the LVAD, result in a diminished pulse
pressure in these patients.1
Pulse pressure of less than 15 mmHg is not palpable in
physical examination and not detected by automated BP
cuffs. Most LVAD patients have low pulse pressure, hence
have no palpable pulse (‘non-pulsatile’) and automated BP
cuff would not be able to measure their BP. For that reason,
the measured and reported BP value of LVAD patients is
mean arterial pressure (MAP).2
BP measurement
Direct measurement of the blood pressure BP with arterial
line is the most accurate and reliable method but is available
only at the inpatient setting. An automated BP cuff is effec-
tive in those LVAD patients that have palpable pulse (‘pulsa-
tile’), which are minority of the patients. If that is the case,
the MAP should be calculated [MAP = (2*DBP + SBP)/3].
For most LVAD patients with low pulsatility, the preferred
method is using a vascular Doppler transducer with manual
cuff (sphygmomanometer). The Doppler transducer is placed
on either the brachial or radial artery or the arterial flow de-
tected in the resting condition. The cuff is inflated and then
deflated slowly. The BP recorded when an arterial flow sound
is heard is approximately the MAP. It is important to note
that when this method is used on a pulsatile LVAD patient,
the value measured is the systolic BP (SBP), and the MAP
would be lower.
• If No palpable pulse—use Dopplermethod—measuresMAP
• Palpable pulse—use automated BP cuff and calculate MAP
from systolic and diastolic BP
BP management
Elevated BP is associated with serious adverse events, includ-
ing ischaemic stroke, intra-cranial haemorrhage, pump
thrombosis, aortic regurgitation, and ventricular
arrhythmia.3,4 The pathophysiologic process is complex and
starts with elevated afterload on the pump, causing a
decrease in pump flow.5 The recommended BP for LVAD pa-
tients is MAP of ≤80 to 85 mmHg.6,7 On the lower part of
the scale, MAP of less than 60 mmHg is associated with hypo-
perfusion and therefore must be avoided. The optimal
target for MAP in LVAD-supported patients is in the range
of 70–90 mmHg.6
Hypertension treatment
Hypertension is common among LVAD patients and is prefer-
ably managed with heart failure medications, as
angiotensin-converting enzyme (ACE) inhibitors or angioten-
sin II receptor blockers (ARB’s), beta-blockers, and
spironolactone.6,7 Special caution is needed with the use of
beta-blockers in patients with RV failure, due to their nega-
tive inotropic effect. Second line medication includes calcium
channel blockers, alpha-blockers, hydralazine, and nitrates.
Patients treated with phosphodiesterase 5 (PDE5) inhibitors
for elevated pulmonary pressure, must not be concomitantly
treated with nitrates due to risk of profound and life-threat-
ening hypotension.
• Most LVAD patients do not have palpable pulse.
• If there is palpable pulse, an automated cuff systemwill give
reliable measurements; otherwise, use a Doppler probe.
• Aim to reach mean arterial pressure of 70–90 mmHg.
• Treat BP with HF medications but with caution when using
beta-blockers, in particular in the presence of RV failure.
Medical therapy during LVAD support
While there is a significant amount of clinical trial data to guide
the use of traditional heart failure (HF) medications in patients
with HF and reduced ejection fraction, similar data to guide
the management of patients with LVADs are not available.
The role of HF medications—ACE inhibitors, ARBs, β-blockers,
mineralocorticoid antagonists (MRAs), and diuretics—in the
care of patients with an LVAD is largely unknown. Most of
the recommended use of these HF medications in patients
with LVADs is based only on consensus agreement.
Factors such as right heart failure, atrial and ventricular ar-
rhythmias, renal dysfunction, and pulmonary hypertension
can compromise the efficiency of an LVAD, resulting in inef-
fective cardiac support and necessitating medical therapy to
improve cardiac function and optimize ventricular unloading.
Observational studies have reported that traditional HF
therapies were moderately prescribed at discharge to pa-
tients with LVADs and were more frequently prescribed to
patients with advanced HF without LVAD support.8 Moderate
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prescription rates suggest clinical uncertainty in the use HF
medication in this population.
The most recent ISHLT executive summary recommended
use of HF medications in patients with LVADs mainly to con-
trol BP. Continuous flow LVADs are afterload sensitive and
therefore pump performance is affected by hypertension. In
addition, poorly controlled hypertension may increase the
risk of aortic insufficiency (AI) and stroke.
The use of beta-blockers is reserved for heart rate control
in the setting of tachyarrhythmia, especially atrial arrhyth-
mias which are common post-LVAD implantation. Due to
the potential negative inotropic effect of these agents on
the right ventricular function, use those agents with caution
in LVAD-supported patients.
The use of neurohormonal blockade drug therapy (NHBDT)
post-LVAD may be beneficial as cardiac angiotensin genera-
tion does increase despite LV unloading, thus activating the
sympathetic nervous system. NHBDT in LVAD-supported pa-
tients is also associated with a significant reversal in adverse
cardiac remodelling and a reduction in morbidity and mortal-
ity compared with LVAD support alone. The use of ACE inhib-
itors/ARB may also protect against angiogenesis and has been
shown to be associated with reduced risk for major gastroin-
testinal bleeding (GIB) and AV malformation related GIB in
patients with LVAD. There is no evidence to support the use
of sacubitril/valsartan over ACE inhibitors after LVAD implan-
tation. Recent observational data have demonstrated a large
decrease in BP associated with sacubitril/valsartan in LVAD
recipients but also improved clinical outcomes.9 Results of
ongoing studies are awaited.
Action:
• Control the LVAD patient’s BP preferably using HF drugs
like ACEI and ARBs.
• Use beta-blocker in the case of tachyarrhythmia but be
cautious in the presence of right ventricular failure.
Anticoagulation and left ventricular assist devices
Current guidelines recommend anticoagulation with vitamin
K antagonist for all patients on left mechanical circulatory
support.6,7 The delicate balance in anticoagulation is manda-
tory for preventing both bleeding and thrombotic events.
Anticoagulant therapy may be evaluated in three different
periods: (1) intraoperative and intensive care unit, (2) inter-
nal medicine ward, and (3) outpatient (home).
Intraoperative and intensive care unit: intraoperative full
dose anticoagulation as in other cardiac surgeries is recom-
mended. Early anticoagulation is needed to prevent throm-
botic events. Intravenous heparin is commonly used as the
primary choice. Intravenous direct thrombin inhibitors such
as bivalirudin and argatroban may be used in patients with
heparin induced thrombocytopenia. Start anticoagulation
with oral vitamin K antagonist once the patient’s condition
is stable.7
Internal medicine ward: Although centrifugal pumps have
shown to be superior to axial flow devices regarding gastroin-
testinal (GI) bleeding and haemocompatibility related ad-
verse events, the target International normalized ratio (INR)
has not been changed and kept between 2.0 and 3.0. How-
ever, some centres have lowered their target INR to 2.0–2.5
for patients with centrifugal pumps, even if this strategy
has not yet been proven effective. Higher values (INR up to
3.5) may be preferred for patients with biventricular support.
Acetylsalicylic acid at the dose of 80–325 mg is routinely ad-
ministered according to the device specifications.
Bridging with intravenous heparin is advised if the INR
level is <2.0. Measurement of both the activated partial
thromboplastin time and factor Xa is used for monitoring
heparin dose.6,7 It has been shown that there is high discor-
dance between activated partial thromboplastin time (aPTT)
and anti-factor Xa (anti-FXa). aPTT may be affected by warfa-
rin use, liver disease, haemolysis and factor deficiencies. The
most common observation in these patients was
supratherapeutic aPTT value with a therapeutic anti-FXa
level.10 Haemolysis and warfarin use may falsely elevate aPTT
resulting in overestimation of heparin concentration and un-
der anti-coagulation.10 Low-molecular weight heparin
(LMWH) may also be used although caution should be
exerted in patients with renal dysfunction. Enoxaparin and
dalteparin have shown to be effective in the mechanical cir-
culatory support population.11 No specific type of LMWH
has been proposed in the guideline.7
Outpatient: Routinely measure of INR level at least once a
week. It has been shown that self-testing of INR at home is
possible and likely to increase the average time in therapeu-
tic range. In one study, miscorrelation between laboratory
and self-testing INR levels were shown and suggested
performing series of individual correlation tests on
patients before instituting home INR monitoring and to
exclude patients in whom the INR level difference is
unacceptable.
Optimal long-term regimen of anticoagulation must be tai-
lored to the recipient and device type. During periods of un-
der targeted INR or during periods of bridging with
un-fractionated heparin or LMWH, follow the patient closely
for pump thrombosis or thromboembolic events.
Bleeding in LVAD recipients and its management is
reviewed in detail in Part 2 of the position paper. Recommen-
dations here also pertain to the outpatient phase.
Table 1 presents management of anticoagulation pre-oper-
ative, peri-operative, and postoperative of left MCS
implantation.
• Anticoagulation is mandatory for all settings of care
followed by close monitoring.
• New oral anticoagulant drugs have not been studied in this
population.
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Heart failure exacerbation in LVAD-supported
patients
Although the LVAD provides continuous and steady flow from
the left ventricle to the aorta, many factors may still compro-
mise its function. Moreover, the function of the LVAD de-
pends on adequate blood flow from the right ventricle.
Therefore, any trigger interrupting RV function or the LVAD
function might result in a clinical presentation of HF.
The assessment of the LVAD patient with HF is based on
the usual evaluation of a non-LVAD patient with HF. Several
points need to be emphasized:
• History taking—Evaluate the patient for whether left heart
or right heart failure symptoms predominate and if their
onset was abrupt or subtle (symptoms that started on a
specific day will help when interrogating past events within
the LVAD memory recordings). Ask if the medical treatment
was changed recently and whether any device related
alarms were noted prior to the symptom presentation.
• Physical examination—Differentiate between right or left
HF symptoms, and accurately measure BP. If MAP >100,
treat with anti-hypertensive drugs to a target MAP <80.
• In cases of fluid overload, prescribe or increase the dose of
diuretics.
• Laboratory exams—Complete blood count, eGFR, liver en-
zymes, Lactic acid dehydrogenase (LDH) level and plasma
free haemoglobin (elevation might suggest pump throm-
bosis), and brain natriuretic protein (BNP) might differenti-
ate cardiac from non-cardiac cause, and INR.
• Electrocardiogram (ECG) and if appropriate ICD interroga-
tion—Look for any tachy/brady arrhythmia that might ex-
plain symptoms.
• Chest X ray—pulmonary congestion might point to pump
failure, pleural effusion, or pneumonia might explain dys-
pnoea, mal-positioning of the device might cause suction
events—consult with an LVAD specialist regarding its
positioning.12
• Echocardiography—must be performed by an experienced
technician. RV function is at times difficult to assess tech-
nically but nevertheless must be determined. Meticulously
search for new valvular dysfunction; specifically, new aor-
tic regurgitation which might explain the acute
decompensation. Assess the position of the interventricu-
lar and interatrial septum.
• Referral to the LVAD specialist for LVAD parameters evalu-
ation, LVAD history interrogation, and recording of the
alarm’s history.
General approach for evaluation of HF
exacerbation in a LVAD patient for the non-LVAD
specialist
As in any other medical setting, meticulous history and phys-
ical examination are the first step. Try to locate a non-cardiac
event as a possible trigger for the decompensation such as
use on non-steroidal anti-inflammatory drugs, infection, and
anaemia, and treat it accordingly. If not found, the patient
must be profiled into left HF, right HF, or both.13
If left HF predominates look for possible triggers. If BP is
high, treat the hypertension targeting MAP <80 mmHg. If
there is significant AI on echo, manage BP and estimate the
need for valve replacement. If there are signs of device mal-
function, consult an LVAD specialist and treat the malfunc-
tion. If pump thrombosis is suspected, treat with IV heparin
and thrombolysis, and even be ready for an emergent sur-
gery. Increase cardiac output by elevating the device speed
if the echo findings support the possibility of inadequate
speed. Treat pulmonary congestion with vasodilators and
diuretics.
If no specific trigger can be corrected, treat with inotropes,
and if this fails, be prepared for pump replacement or high
urgency cardiac transplantation.
If right heart failure predominates—rule out ‘normal’
causes of RV failure like pulmonary embolus, severe tricuspid
regurgitation, cardiac tamponade, and RV infarction. If none
of them exists, insert a Swan-Ganz catheter, treat with IV di-
uretics and if applicable also pulmonary vasodilators and per-
form an echocardiogram. If the patient does not respond,
treat with inotropes, and if this fails, assess for RV mechanical
support or cardiac transplantation.
• Assessment of the LVAD patient with HF is like the
non-LVAD with emphasis on interrogation of past events
if possible.
Table 1 Suggested management of anticoagulation pre-operative, peri-operative and postoperative of left MCS implantation7
Management of anticoagulation pre-operative, peri-operative, and postoperative of left MCS implantation Class Level
Early postoperative anticoagulation starting with IV anticoagulation, followed by vitamin K antagonists are recommended I C
The use of low-molecular weight heparin as an early postoperative anticoagulation regimen should be considered IIa C
A postoperative INR target between 2.0 and 3.0 is recommended I C
The use of acetylsalicylic acid is recommended I C
The use of low-molecular weight heparin for bridging during long term support is recommended I C
Re-evaluation of antithrombotic therapy during bleeding episode is recommended I C
The use of novel oral anticoagulants is NOT recommended III B
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• Treating HF exacerbation starts by deciding whether left or
right failure predominates. In most of the cases, it will be
right-sided heart failure.
• In the cases of left-sided heart failure, keep good control
of the BP and fluid status and consult the heart failure spe-
cialist in order to evaluate the pump history.
Kidney dysfunction in LVAD-supported patients
The vast majority of HF patients referred for LVAD therapy
have had increasing symptoms and signs of congestion with
volume overload.14 Moreover, growing evidence has
established the pathophysiological importance of congestion
in HF disease progression.15 The goal therefore is to relieve
congestion through achieving a state of euvolemia, mainly
through the use of judicious diuretic therapy. The appropriate
use of diuretics however remains challenging, especially
when shock, worsening renal function, diuretic resistance,
and electrolyte disturbances occur.16 The interdependence
between heart and kidney has been a topic of extensive re-
search for decades. Intuitively, progressive renal dysfunction
is often attributed to hypoperfusion of the kidney due to pro-
gressive impairment of cardiac output. However, a drop in
systemic BP, venous congestion and intra-abdominal pressure
are haemodynamic parameters strongly associated with
worsening renal function in heterogenous populations of
HF.16
As LVAD use increases, so does the number of patients
with LVADs who also have kidney disease, with limited data
on how best to care for them. Following LVAD implantation,
kidney function may improve in the short term, particularly
if central venous congestion/low renal blood flow were re-
sponsible for the poor glomerular filtration rate.17,18 Individ-
uals with glomerular filtration rates chronically <30 mL/
min/1.73 m2, including those treated with maintenance dial-
ysis, are generally ineligible for destination LVADs as they
have a very poor outcome.18 As such, extra care is warranted
to avoid the need for renal replacement therapy in LVAD
patients.
Patients who develop acute kidney injury and require dial-
ysis following LVAD implantation have high mortality rates.18
Although haemodialysis is the most common modality for pa-
tients with LVADs, peritoneal dialysis might be an option in
selected cases taking into consideration the risk for driveline
infections.19 However, peritoneal dialysis may be associated
with lower risk for bloodstream infection and fewer haemo-
dynamic shifts.19
• Patients who develop acute kidney injury requiring
haemodialysis while on LVAD have poorer prognosis.
• Peritoneal dialysis is preferred in the appropriate LVAD pa-
tient on the need for renal replacement therapy.
Liver dysfunction in LVAD-supported patient
Liver dysfunction is common in chronic and acute decompen-
sated HF. The cardio-hepatic interaction in HF is related to
both increased venous pressure and forward failure of the
left ventricle. Increased venous pressure is associated with el-
evated cholestatic liver enzymes, while reduced cardiac out-
put results in liver injury and subsequent elevated
transaminases.20 In patients with advanced HF, potential can-
didates for LVAD implantation, liver dysfunction is of impor-
tant prognostic value.
The Model for End-stage Liver Disease (MELD) score is pre-
dictive of outcome in patients with end-stage liver disease.
Similarly, the MELD score may be helpful in prediction of out-
come in patients with advanced HF, who are screened for
LVAD implantation.21 Yang et al.22 demonstrated that a
MELD-XI (MELD excluding INR) score <17 was associated
with an improved outcome in 255 patients after continuous
flow LVAD implantation. In addition, assessment of liver stiff-
ness, as a marker of liver fibrosis, with ultrasound
elastography may provide important prognostic information.
In a study with 28 patients with continuous flow LVADs, it
was demonstrated that liver stiffness correlated with
invasively measured central venous pressure and extent of
liver fibrosis from biopsies. Furthermore, an improvement
in liver stiffness after LVAD implantation was noted.23
Several studies have demonstrated that liver dysfunction is
(partly) reversible after LVAD implantation. In a cohort of 309
continuous flow LVAD patients, Russell et al.24 noted that
6 months after implantation, alanine transaminase (ALT), as-
partate transaminase (AST), and total bilirubin had signifi-
cantly decreased. In a more recent study, it was shown that
after more than 3 years of LVAD support, hepatic function
is still preserved.25 However, worsening of liver function
may occur as well after LVAD implantation. In a cohort of
270 LVAD patients, up to 47.8% developed some degree of
post-operative liver dysfunction. Patients with combined ele-
vated transaminases and total bilirubin had a significant
worse prognosis compared with patients without liver dys-
function after implantation.26 Although the exact mechanism
is most likely to be multi-factorial, post-operative liver dys-
function may be related to pre-operative liver dysfunction
and inflammatory state and post-operative right ventricular
failure and venous congestion.
Therefore, careful assessment of liver function during
pre-operative patient selection and during post-operative
monitoring is critical for good outcomes after LVAD
implantation.
MELD = 3.78*Ln (Bili) + 11.2*Ln (INR) + 9.57*Ln (Cr) + 6.43.
MELD-XI = 5.11*Ln (Bili) + 11.76*Ln (Cr) + 9.44.
In the MELD calculation, any variable with a value less than
1 is assigned a value of 1 to avoid negative scores.
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• In most patients after LVAD implantation liver, functions
will be preserved and even improved.
• Post-LVAD liver dysfunction may be due to a pre-operative
inflammatory state and post-operative right ventricular
failure and venous congestion.
Management of infections in LVAD-supported
patients
Patients with LVAD comprise several risk factors rendering
them more vulnerable for infection than other patient popu-
lations. Per definition, LVAD patients form a population with
advanced HF, which is commonly associated with numerous
comorbidities, such as diabetes mellitus or renal impairment,
which increases the risk for infection.27 Repetitive hospitali-
zations during acutely decompensated HF, often infection-
triggered,28 in the months and years preceding LVAD implan-
tation expose this patient population to hospital-associated
pathogens, allowing for potential colonization with fre-
quently antibiotic-resistant pathogens. Advanced disease in
general is associated with a compromised immune system,
a phenomenon described as immune-senescence, highly
prevalent in patients with advanced HF.29–31 Noteworthy, in-
fection is among the most frequent reasons for
non-cardiovascular death in HF patients.32 Moreover, the
yet obligatory transdermal driveline frequently serves as port
of entry for pathogens. Once acquired, an infection weighs
heavier in LVAD-assisted patients than it does in other popu-
lations since it is associated with a significantly worse
outcome.32 Beyond the compromised immune system of this
vulnerable patient population, two other major reasons ac-
count for the poor prognosis associated with infection in
LVAD patients. One reason is the difficulty in diagnosing in-
fection. Signs and symptoms of infection in LVAD patients
are very versatile and range from scant erythema or malaise
to high-grade fever or sepsis; therefore, early consideration
and identification of infection is of paramount importance.
The second reason is the difficulty to successfully treat device
infection. As with any other implanted foreign material, path-
ogens tend to form biofilms on the foreign surface of any
component of the implanted LVAD. Within biofilms, patho-
gens are inherently resistant to the host immune system
and extremely difficult to eradicate.
Biofilms
Biofilms are communities of microorganisms attached to any
surface such as metals and minerals, plant tissues, dental
plaque and on implanted medical devices. Biofilm formation
plays a significant role in the persistence of bacterial infec-
tions and is a major contributor to and virulence determinant
of LVAD-specific infections.33,34 Pathogens capable of forming
biofilms are typically Staphylococcus aureus and Staphylococ-
cus epidermidis; however, less common, Pseudomonas and
Enterobacteriaceae species as well as Candida albicans also
form biofilms on implanted foreign material. After irrevers-
ible attachment to the foreign surface, they produce a matrix
of extracellular substances (composed of DNA, polysaccha-
rides, and proteins) that surrounds the foreign material and
protects biofilm-producing pathogens both from the host im-
mune system and from circulating antibiotics. Pathogens
spread, on the one hand, by migration along the foreign sur-
face and, on the other hand, by a process called dispersion,
during which pathogens detach from their original colony
and translocate to a new location.35 This inherently protec-
tive behaviour makes it extremely difficult, if not impossible,
to eradicate biofilm-associated infections.
Uniform definition of infections in LVAD-assisted patients
Infections in LVAD patients can be differentiated according to
the standardized classification of infections, formulated by
the ISHLT Infectious Disease Working Group in 2017.27
LVAD-specific infections: These infections only occur in
LVAD patients and are directly related to the implanted hard-
ware (i.e. pump, inflow cannula, outflow graft, driveline) or
the body surfaces containing it (i.e. pump pocket, anastomo-
ses, driveline tunnel). These infections are often difficult to
diagnose conclusively, and, secondary to the common in-
volvement of biofilm formation, difficult to eradicate.
LVAD-related infections: These infections may also occur in
non-LVAD patients. However specific considerations apply, if
present in LVAD patients. The following entities belong into
this group: endocarditis, blood stream infections,
mediastinitis, and sternal wound infection.
Non-LVAD-related infections: These infections are inde-
pendent or not directly associated with the presence of an
LVAD and may occur in any severely sick patient. Such infec-
tions are mainly lower respiratory tract infections like pneu-
monia, blood stream infections, urinary tract infections, and
gastrointestinal infections.
Epidemiology of infections in LVAD-assisted patients
With an incidence of up to 37% of all patients after LVAD im-
plantation, infections are the most common adverse event in
patients with mechanical circulatory support. Interestingly,
the most frequent infections in LVAD patients are non-
LVAD-related infections.32 They occur predominantly within
the first 3 months after LVAD implantation, indicating that
these are nosocomial infections. Pneumonia and urinary tract
infections are most common infections among non-LVAD-re-
lated infections with an incidence of up to 10.8% (0.45 events
per patient-year) and 10.6% (0.44 events per patient-year),
respectively. Non-LVAD-related infections are followed by
VAD-specific infections, among which driveline infections
are by far the most frequent, occurring in 9.1% (1.28 events
per patient year) of patients within 3 months after LVAD im-
plantation, and in 29.3% (1.20 events per patient year) of pa-
tients thereafter.
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Challenges in management of biofilm associated infection in
LVAD patients
Whereas device removal is a routine therapeutic option in
patients with device infection of devices other than LVADs
(e.g. prosthetic joint material, cardiac pacemakers or implant-
able cardioverter defibrillators), a pump exchange or removal
of an infected LVAD is usually associated with high mortality,
often outweighing the benefit of such an intervention. Usu-
ally the only possibility in infected LVAD patients requiring
LVAD removal is heart transplantation.
In summary,
• Be aware of the vulnerability of this patient population.
• Meticulous line and wound care may prevent infection.
• Early consideration of the possibility of an infection allows
prompt diagnostic work up and initiation of therapy,
where indicated.
• Remember that LVAD can delay the symptoms of sepsis so
consider early use of antibiotics.
• When in doubt, take swabs and blood cultures (ideally 3
sets of 2 in 24 h) and/or contact your LVAD centre.
• Always involve your LVAD centre when suspecting an in-
fection in your LVAD patient, irrespective of LVAD-specific,
LVAD-related or non-LVAD related.
• Optimal management of suspected infection in an LVAD
patient necessitates the collaboration of a multidisciplin-
ary team of infectious disease specialist and/or clinical mi-
crobiologist, cardiologist, and cardiac surgeon.
• Photo documentation is useful.
Diagnostic work-up:
• Careful history and review of symptoms may prompt early
suspicion of infection.
• A detailed physical exam, always including inspection of
the driveline exit site and surgical wounds, is warranted.
• Lab test include a complete blood count and serial assess-
ment of C-reactive protein (CRP) or erythrocyte sedimen-
tation rate (ESR).
• If purulent effusion is visible, always take swabs before ini-
tiation antibiotic treatment.
• Take three sets of blood cultures at different time points
within the first 24 h of suspicion, at least the first set be-
fore initiating antibiotic therapy.
• If a central or peripheral line is present, take two sets of
blood cultures simultaneously, one from the central or pe-
ripheral line, the other from a non-related peripheral site.
Differential time to positivity may allow differentiation be-
tween a LVAD-related and a non-LVAD-related blood
stream infection.
• Imaging can help in diagnosing the source of infection.
Routinely perform a chest X-ray when in suspicion of an in-
fection in your LVAD patient. Ultrasound can help detect-
ing fluid collections and differentiate between local and
extended infection. Single-photon emission tomography
(PET) in combination with computed tomography (PET-
CT) may be very useful in diagnosing and/or differentiating
LVAD-specific and LVAD-related infections.
• Patients with LVAD are precluded from MRI.
Therapeutic approach:
• Avoid initiation of antibiotic therapy without prior swabs
and blood cultures.
• Involve the LVAD centre when initiating antibiotic therapy.
• Even in cases of superficial infection without signs of sys-
temic disease, initiation of antibiotic therapy is not to be
deferred until the culture results are available but later
modified accordingly.
• In case of clinical signs of infection and negative culture re-
sults, start empirical antibiotic therapy and evaluation
based on clinical response.
• In case of systemic disease or sepsis, empirical IV antibiotic
therapy must cover Staphylococcus, Pseudomonas, and En-
terobacteriaceae species.
• Take the local (institutional) resistance profile into account
when initiating antibiotic therapy.
• Avoid rifampicin because of its interference with vitamin K
antagonists.
• Signs and symptoms of infection in LVAD patients are very
versatile and range from scant erythema or malaise which
quickly deteriorates to high-grade fever or sepsis.
• Early recognition of infection is of paramount importance.
• If an infection is suspected, the use of empiric antibiotic
therapy is advised
Diabetes mellitus, obesity, and COPD as a major
comorbidity in the LVAD patient
DM is common among LVAD patients, with an estimate prev-
alence of 40%.36 There are conflicting data regarding the as-
sociation of DM with increased rate of mortality and
adverse events including stroke, pump thrombosis, and infec-
tion after LVAD implantation.36–39 This uncertainty regarding
the role of DM on outcomes after LVAD stands in contrast to
the fact that LVAD implantation is associated with a signifi-
cant improvement in DM status, manifested as lower Hb
A1c, lower fasting glucose and decreased insulin
consumption.40–42 Current guidelines recommend screening
for DM before LVAD implantation and consider excluding pa-
tients with DM and severe end-organ complications from
LVAD candidacy.7 The data on DM in LVAD recipients gener-
ally apply to type 2 DM as there is little information on pa-
tients with type 1 diabetes.
Treatment of DM in LVAD patients should follow guide-
lines DM treatment in HF patients. In the new era of SGLT2
inhibitors, it is advised to use these new anti-diabetic drugs
LVAD management by the non-LVAD specialist: during hospitalization and at discharge 7
ESC Heart Failure (2021)
DOI: 10.1002/ehf2.13590
carefully as there are no data regarding this drug in this group
of patients.
Obesity
Obesity is not associated with increased mortality after LVAD
implantation; however, it is associated with some serious
complications including device related infections, right-sided
heart failure and pump thrombosis. Therefore, weight loss
counselling is recommended as part of the evaluation before
LVAD implantation and including morbidly obese patients as
LVAD candidates must be performed cautiously. On the other
hand, it is noteworthy that bariatric surgery after LVAD im-
plantation is a safe and feasible option,43 at times even en-
abling recovery from the LVAD.44
COPD
Severe chronic obstructive pulmonary disease (COPD) pa-
tients are not eligible for LVAD implantation due to increased
surgical risk and poor ability to recover after major chest sur-
gery. On average, lung function does not improve after LVAD
implantation.45 Mild COPD is not a contra-indication for LVAD
if there is no secondary RV failure.
• LVAD implantation is associated with a significant improve-
ment in DM status.
• Pre-LVAD implantation weight loss is beneficial.
• Pre-LVAD implantation obesity is associated with compli-
cations including device-related infections and right-sided
HF and pump thrombosis.
• Mild COPD by itself is not a contra-indication for LVAD and
not complicated by secondary RV failure
Aortic insufficiency following LVAD implantation
One of the unique features that may develop following im-
plantation of a continuous-flow LVAD is AI. In the presence
of an LVAD, AI leads to a circulatory loop, with a portion of
LVAD output flow regurgitating through the aortic valve to
the left ventricle and then back through the device, leading
to ineffective forward flow, and resultant organ
mal-perfusion and increased LV diastolic pressures.
The aetiology of continuous-flow LVAD-associated AI is due
to several factors, including reduced valve opening, altered
blood flow dynamics, pan cyclic transvalvular gradients, high
shear stress, and leaflet mal-coaptation. These processes pro-
mote leaflet fusion, valve degeneration, and aortic wall re-
modelling, which ultimately lead to AI.46
In a retrospective study of 184 LVAD cases from the Duke
University Medical Center, LVAD implantation was associated
with significant worsening of AI relative to the nonsurgical
patients with end-stage HF.47
In a retrospectively analysed group of 237 patients im-
planted with HeartMate II LVAD at the Minneapolis Heart In-
stitute, moderate or severe AI occurred in 32 (15.2%)
patients. Freedom from moderate or severe AI was 94%,
76%, and 65% of patients at 1, 3, and 5 years, respectively,
and there was no difference in survival between recipients
who developed significant AI and those who did not. Patients
who had an aortic valve that opened with every beat were
less likely to develop AI compared with those having intermit-
tent opening or none at all.48
In a meta-analysis following a systematic literature search,
which found eight studies totalling 548 patients with
continuous-flow LVADs, the pooled incidence of de novo AI
was 37%. Factors influencing the development of AI and its
progression were older age, being female, duration of LVAD
support and persistent aortic valve closure.49
In patients going into LVAD surgery with a pre-existing clin-
ically significant AI, several surgical solutions have been tried
and suggested.49–51 These techniques were found effective in
reducing AI and durable, with follow-up extending into
2 years, although early survival favoured those without the
need for aortic valve central closure.
The safety of long-term continuous-flow LVAD support af-
ter aortic valve closure was studied by the Texas Heart Insti-
tute group in 16 patients and compared with those of 510
LVAD recipients without concomitant aortic valve closure.
Survival was similar for LVAD-only patients and aortic valve-
closure patients for a 2 years follow-up. There were no
deaths related to aortic valve closure.52 The Columbia Univer-
sity Medical Center group in New York presented a group of
56 patients with pre-existing mild AI who underwent
continuous-flow LVAD implantation and compared outcomes
between 41 patients who underwent aortic valve repair and
those 15 patients who did not. Freedom from progression
of AI to moderate or severe at 2 years was significantly more
prevalent in the group of patients who underwent aortic
valve repair compared with those who did not.53
Nowadays, most surgeons implanting LVADs prefer replac-
ing an insufficient aortic valve during LVAD surgery with a
bioprosthesis rather than closing the orifice. The approach
to AI that develops late after LVAD implantation is different,
as any repeat surgical intervention in the aortic valve may in-
volve increased surgical risk. A non-surgical technique for
closing the regurgitant aortic valve was first described by
the group from Freiburg, by using a trans-catheter closure
of the native aortic valve with an Amplatzer occluder with
self-expanding double discs and its connecting waist.54 This
technique has been reported so far in more than a dozen of
patients by several groups with a significant reduction of AI,
improvement of cardiac haemodynamics and reduction of
the pulmonary capillary wedge pressure.55
The first reports on successful treatment of severe AI in
LVAD implanted patients using the transcatheter aortic valve
replacement (TAVR) technique, came out in 2012 resulting in
an immediate and long standing reduction of the AI.56
The largest group of patients with continuous-flow LVADs
who underwent TAVR implantation was reported by the group
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from the Piedmont Heart Institute in Atlanta. They reported
nine patients with resolution of AI, a significant improvement
of the New York Heart Association classification from the time
of implant to 6 months, and 89% survival at 6 months.
These last studies favour the TAVR as the current treatment
of choice for LVAD patients who develop symptomatic AI.57
• Patients with significant AI going into LVAD surgery are
treated by most surgeons by replacing the insufficient aor-
tic valve with a biologic prosthesis during LVAD surgery
rather than closing it
• For LVAD patients with severe AR a TAVR is a considerable
option.
In the surgical ward
Anaesthesia for non-cardiac surgery of the
LVAD-supported patient
Approximately 30% of all LVAD-supported patients will re-
quire non-cardiac surgery, most commonly endoscopies or in-
vasive cardiology interventions but could also be from any
other discipline and either elective or urgent.58 Successful
treatment of these patients requires a multidisciplinary ap-
proach, which includes the anaesthesiologist, cardiologist,
LVAD support nurse, and perfusionist.59 In recent years, more
and more procedures requiring anaesthesiologist support in
LVAD patients are carried out in non-LVAD centres, often
out of the operating room, and often by a general
non-cardiac anesthesiologist.59,60
Basic LVAD physiology
It is vital to understand that the LVAD patient is preload de-
pendent, and afterload sensitive. Factors critical to preload
in these patients include volemia, positioning, surgical tech-
nique (laparoscopic vs. open), arrhythmias, and right ventric-
ular function. Afterload sensitivity means that hypertension
can decrease flow causing end organ damage. Recommended
MAP is 70–90 mmHg.58,59,61,62
Pre-operative evaluation
Prior to surgery it should be determined which LVAD the pa-
tient has (HM II™, HW™, HM3™) so that the appropriate console
can be arranged. Medications and end organ function must be
determined. Review the most recent blood tests including co-
agulation, renal and hepatic function, and LDH as a marker of
pump thrombosis. A recent echo will provide vital information
on the cannula position, valvular function, and the right ven-
tricular function. A decision on pre-operative stopping of the
anticoagulation must be taken on a case by case basis with
the risk of bleeding being weighed against the risk of a pump
thrombus.58,61,62 When possible, it is preferred to perform
the surgical procedures in an LVAD centre with an experienced
cardiac anaesthesiologist. Low cardiac risk surgical interven-
tions (such as superficial dermatological surgeries, dental, mi-
nor gynaecological interventions, eye surgeries, etc.) in
patients with no major comorbidities can be performed in a
non-LVAD centre preferably with an access (even remotely)
to LVAD specialists. LVAD specialized centres are reserved
for major procedures in patients with significant comorbidi-
ties, and where post-operative pharmacological support is
likely.59,60 ICD’s need to be de-activated (with a magnet on
the ICD) to allow operation with no inappropriate shocks.
Intraoperative monitoring
During the surgical procedure, the LVAD must be connected
to an adequate power source (preferable mains), and param-
eter monitoring.61 Standard monitors can be used.
Non-invasive BP monitoring is reliant on pulsatility and is only
successful in approximately 50% of LVAD patients. Doppler
ultrasound on the radial artery is successful in 94% of
patients.61 Invasive (intra-arterial) BP monitoring is the gold
standard, but its insertion may be challenging and require
ultrasound or Doppler guidance. The use of arterial lines
has decreased over the years but is always indicated for ma-
jor surgery especially with expected fluid shifts and vasopres-
sor/inotrope use.58,61,62
Pulse oximetry is dependent on pulsatility and therefore
may not record. Serial arterial blood gases can be taken to
monitor oxygenation, and cerebral oximetry can be used to
ensure brain oxygenation.58,62 A central venous line or pul-
monary artery catheter may be indicated for high risk proce-
dures or for unstable patients. A trans-oesophageal echo has
to be available for the diagnoses and treatment of crisis
situations.58,61,62
Anaesthetic choice
Regional or neuroaxial anaesthesia is rarely used due to coag-
ulopathies and anticoagulation and the subsequent risk of
bleeding and complications. Monitored anaesthesia care
(MAC) is commonly used especially in gastro and cardiology
cases. Care must be taken with sedation and spontaneous
ventilation to avoid hypoxia and hypercarbia. General anaes-
thesia is indicated for surgical procedures that require intuba-
tion. Drug choice is limited to drugs, which will maintain
contractility, preload, and afterload. Care must be taken with
positive-pressure ventilation to avoid high tidal volumes and
high positive end-expiratory pressure (PEEP) to maintain
preload.58,61–63
Patient positioning
Trendelenburg (head down tilt) can augment venous return
and cause RV dysfunction. Anti-Trendelenburg (head up)
and lateral decubitus (side) can reduce preload and LV filling,
causing hypotension. Positioning has to be performed
gradually and may require a fluid bolus. Prone position may
also reduce preload and can also cause LVAD inflow
obstruction.58,62
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Surgical technique
Laparoscopy can decrease preload which can decrease pump
flow and cause hypotension. If the patient becomes unstable
the insufflation pressures must be decreased. One-lung venti-
lation is to be avoided where possible due to the likelihood of
hypoxia and hypercarbia which increase pulmonary vascular
resistance (PVR) and may cause RV failure.62
Haemodynamic management
The key targets in the management of the LVAD patient are
to maintain MAP 70–90 mmHg, to protect the right ventricle,
to maintain adequate preload, and to maintain afterload.
Pump parameters such as pulsatility index (PI), pump power,
pump flow are used to help diagnose problems.58,59,61,62
Intraoperative challenges
‘Suction event’ refers to when the interventricular septum
shifts towards the inflow cannula of the LVAD. It results in re-
fractory hypotension, low pump flow, low PI, ventricular ar-
rhythmias, and haemodynamic collapse. Causes can include
hypovolemia, high pump speeds, RV dysfunction, high PVR,
and vasoplegia. Treatment includes fluids, vasopressors, a re-
duction in pump speed, and RV optimization (nitric oxide,
milrinone, dobutamine, and adrenaline).58,62
Bleeding is not uncommon with 40% of patients requiring
blood products. This is due to a combination of acquired type
2a Von Willebrand Deficiency, AVMs due to continuous flow,
and anticoagulation.58,62
Arrhythmias occur in 30–50% of patients and can be atrial
or ventricular. They can cause decompensated HF and insta-
bility. Suction event must be ruled out. A stable patient with
an arrhythmia can be treated conservatively with amioda-
rone or lidocaine. If the patient is unstable cardioversion is in-
dicated, and pump speed is adjusted if a suction event is
suspected.58,62
Cardiac arrest can be difficult to detect without electrocar-
diogram monitoring and will often result in PETCO2 being un-
der 20 mmHg. Resuscitate as non-LVAD patients (see relevant
section in this manuscript).58,62
Post-operative care
Post-operative extubation and recovery care are applied ac-
cording to the standard procedures whilst avoiding abrupt
changes in preload, afterload, and contractility. A multidisci-
plinary team approach is adopted. Minor cases can safely
be monitored in the regular Post-Anesthesia Care Unit
whereas major cases would likely benefit from intensive care
unit (ICU) or intensive cardiac care unit (ICCU). The ICD
should be reset.58,63
• The LVAD patient is preload dependent and afterload
sensitive.
• Critical factors influencing preload in these patients include
blood volume, positioning, surgical technique (laparoscopic
vs. open), arrhythmias, and right ventricular function.
• Afterload sensitivity means that hypertension can de-
crease flow causing end organ damage.
• Special LVAD centres are reserved for the major surgical
procedures especially for patients with significant comor-
bidities, and where pharmacological support is likely to be
needed.
• For post-operative care, a multidisciplinary team approach
is preferable.
• Minor cases can safely be monitored in the regular
Post-Anesthesia Care Unit whereas major cases would
likely benefit from ICU or ICCU.
Non-cardiac surgery in LVAD patients
Patients with LVADs who are in need for non-cardiac surgery
demonstrate unique concerns that require specifically ad-
dressed peri-surgical assessment to minimize the risk for
complications. This include the need for adequate
intra-operative BP monitoring, peri-operative anticoagulation
management, modifications to the surgical access site due to
anatomic considerations, and management of intraoperative
device malfunction and postoperative complications includ-
ing cardiovascular and cerebrovascular events.59
Most common minor procedures performed in LVAD pa-
tients are gastrointestinal endoscopic examinations.59,64,65
Other common procedures are related to implantable
cardioverter devices (e.g. device extraction) and other elec-
trophysiological procedures such as ablations.59
Abdominal surgeries in LVAD patients are increasingly per-
formed due the increased prevalence of LVAD-supported pa-
tients and their improved longevity. Abdominal surgery in
LVAD patients can be challenging due to both the use of
anti-thrombotic treatment and to access-site restrictions.
Pre-operative computed tomography (CT) scan are useful to
locate pump pocket and driveline location.
A study which included seven LVAD patients who
underwent emergency abdominal laparotomy found 28%
peri-operative mortality rate. All surgeries were performed
using a midline incision without xiphoidal extension.66
Elective laparoscopic procedures are also feasible in LVAD
patients. A study comprising of 17 elective laparoscopic pro-
cedures in LVAD patients described the periumbilical open
Hasson technique as the most common abdominal entry
technique used. No cases were converted to open surgery.
Peri-operative thrombotic events or LVAD complications
secondary to holding anticoagulation were not reported.67
Retrospective data from a study comprising 246 patients
and 702 procedures demonstrated increased risk of acute
kidney injury (18%), intra-operative hypotension (27%, hypo-
tension defined as MAP <70 mmHg over 20 min), elevated
LDH levels (2.6%), and bleeding complications (6.4%).59
Peri-operative mortality was 5.3%.
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Intra-operative blood-pressure monitoring frequently re-
quires the use of invasive intra-arterial catheter. However,
this need is dependent upon the LVAD type, patient and sur-
gical characteristics, and anaesthetic management and was
more frequently reported in lower versus higher volume
institutions.68 Moreover, the use of a Doppler probe with a
manual sphygmomanometer or a slow-deflation cuff has
been shown to increase non-invasive monitoring success
rates.69,70Target values defining hypotension in LVAD pa-
tients differ from the ones used in the general non-LVAD pop-
ulation. A cut-off of <70 mmHg to define hypotension is
mostly used.59 Moreover, the aetiology of hypotension in
LVAD patients commonly differs from the general surgical
population and may include the development of device
thrombus, suction events, and right ventricular failure.59 Al-
terations to previously stable device settings are rarely (if
ever) needed intraoperatively.65
Anticoagulation management in LVAD patients during the
peri-operative period remains challenging and is most often
determined on a case-by-case basis. Management of active
bleeding in LVAD patients does not differ from the protocols
used in non-LVAD patients) Table 2).
Acute kidney injury (AKI) that developed in the first week
of surgery was observed in 17% of LVAD patients post
non-cardiac surgeries (NCSs).59 Peri-operative characteristics
independently associated with AKI included major proce-
dures, invasive arterial BP monitoring, and pre-operative
fresh frozen plasma transfusion; the latter most probably
serve as surrogates for the complexity of the patient.
In conclusion, key decisions in LVAD patients undergoing
major NCS include the presence of LVAD coordinator/anaes-
thesiologist during surgery, the optimal anticoagulation
regimen, and the need for invasive haemodynamic monitor-
ing. (Table 3).
• Record pump parameter 24 h before elective NCS and
monitor trends.
• Consider IV hydration if ‘nil by mouth’ is prolonged.
• Establish BP monitoring BEFORE induction of general
anaesthesia
• Maintain MAP 70–90 mmHg.
• De-activate ICD.
• For abdominal conditions, laparoscopic surgery if feasible
may be safer.
• Recommence IV heparin 24–48 h post-NCS until therapeu-
tic INR levels.
During hospitalization and at discharge
Driveline issues
The driveline (DL) is a cable that exits the body at the lower
abdominal wall connecting the intra-corporeal pump to the
external controller and the energy supply delivering power
and data. The DL consists of a central strength cable
surrounded by six electrical conductors, three primary (two
for energy supply and one for data) and three backups. Han-
dling of the DL is usually performed by the patient himself
and his close caregivers. If the close caregiver accompanies
the patient, it is preferred to allow him to continue handling
the DL and dressing as he is experienced and has been qual-
ified for that. In case of an emergency when there is no close
caregiver, other healthcare providers will be required to take
Table 2 Suggested anticoagulation management
Consequence of bleeding Non-life threatening Life threatening
Elective surgery • Stop warfarin and aspirin for 5 days.
• Bridge with IV heparin.
• Stop warfarin and aspirin for 5 days.
• Bridge with IV heparin.
Urgent/emergent surgery If required intra-operative:
• Anticoagulation reversal with FFP
• Platelet transfusion
Pre-emptive:
• Anticoagulation reversal with FFP.
• Platelet transfusion.
FFP, fresh frozen plasma.
Table 3 Suggested invasive monitoring
Likelihood of instability
Non-general anaesthesia General anaesthesia
Low probability High probability Low probability High probability
CVC Yes Yes Yes
AL Yes Yes Yes
PAC Insert sheath
TEE Make available
AL, arterial line; CVP, ventral venous catheter; PAC, pulmonary artery catheter; TEE, trans-oesophageal echo.
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care of the DL. There are various protocols for handling the
DL, and mainly, among them all, the common denominator
is that the principle of sterility must be kept.
When approaching an LVAD patient by a non-LVAD special-
ist, the following issues related to the DL need attention:
(1) Verify connection of the cable to the controller.
(2) The cable is complete and not damaged.
(3) The cable is straight and not twisted or kinked.
(4)The cable is secured to the controller.
(5) The dressing is clean and undamaged.
(6) The cable is fixed to the body.
The routine care includes keeping the DL from external dam-
age, cleaning, dressing, fixation, and shower issues.
Self-care of the driveline
Keeping the DL from external damage: keep the DL fixed to
the abdominal wall and avoid kinking or pulling of the DL.
Cleaning: wipe the skin around the DL away from the exit
site and not vice versa with a sterile pad rinsed in Alcohosept
(chlorhexidine 0.5% + alcohol 70%) or by ChloraPrep (chlor-
hexidine 2% + alcohol 70%).
Dressing—There is no one specific recommended protocol,
and the dressing manner is affected mainly by equipment
availability and by local experience. Before applying a dress-
ing, ask for any known allergic-hypersensitivity reaction to
the dressing employed. There is no benefit in daily dressing
change, and the recommendation is to change the dressing
twice a week in a sealed dressing or once a week in a transpar-
ent dressing. This is applicable only to intact and uninfected
exit sites, as the presence of infection or secretion will require
more frequent dressing changes. Surrounding the DL exit site,
around the DL, a simple sterile pad, or an antimicrobial or a sil-
ver dressing71 should be used. A transparent chlorhexidine
dressing, allowing daily control over the wound and requiring
only once a week replacement, is widely used. The only disad-
vantage in that kind of dressing is that it cannot absorb any se-
cretion from an unhealed or infected DL exit site. The
replacement of the DL dressing must be made in sterile tech-
nique and can be performed when needed by the nursing
team similar to the way a dressing of a pick Line is performed.
Fixation —Movement of the DL may cause injury or bleed-
ing and infection at the DL exit site. There are many types of
fixators with no advantage of one over the other. Without
any relevance to the fixator used, the cable must always be
attached to the abdominal wall. The fixation is replaced as
needed approximately between weekly and monthly.
Shower—Showering requires preparations. The dressing
must be covered with any method (large adhesive, nylon
wrap) in order to prevent water penetration. The accessory
equipment (batteries and controller) is inserted into a
dedicated waterproof bag. Showering with the cable plugged
in is prohibited. Optimal timing for the DL dressing change is
after showering, and the patient is advised to plan that
ahead.72 Some LVAD programmes allow showering every
day; some twice a week; and others, once a week. In any
case, it is advisable to avoid showering until the exit site
wound has healed. Aburjania et al. showed a significant re-
duction in DL infections if weekly showering.73
Infections —Infections are the Achilles heel of the LVAD
system, among which DL infection is the most common, re-
ported at a range of 15–40% in the 3 years post-LVAD implan-
tation. These infections cause significant morbidity, progress
to sepsis, and even be life threatening.
Preventing infection —Preventing infection in hospitalized
patients is crucial. Eradication of DL infection or other
LVAD-related infection is problematic in the presence of a
foreign body that cannot be extracted. The importance of
hand hygiene must not be underestimated. Firm fixation of
the DL to the abdominal wall is very important for the pre-
vention of DL infection by reducing damage caused to DL exit
site. A fall or pull of the bag containing the batteries and con-
troller are the primary cause of DL infection.27 In case of bag
fall and pulling of the DL, the attending healthcare provider
must perform an assessment of the wound. If signs of dam-
age or bleeding at the DL exit site are observed, empiric anti-
biotic therapy is indicated for at least 1 week. First generation
Cephalosporin is the preferred antibiotic class covering most
of the agents causing skin infection. Replacement of the
dressing by an experienced caregiver or a skilled staff mem-
ber in the proper sterile technique is important for the pre-
vention of DL infection.
In every hospital admission, the patient’s
methicillin-susceptible S. aureus and methicillin-resistance
S. aureus status must be reviewed and treated accordingly.
The use of secondary prophylaxis for non-cardiac procedures
such as dental, gastrointestinal respiratory, genitourinary, or
cutaneous in LVAD-supported patients has not been studied
yet. Although in the American Heart Association Scientific
Statement27 the routine use of antibiotic prophylaxis in pa-
tients with indwelling devices is not recommended, the
2013 ISHLT ‘Guidelines in Mechanical Circulatory Support’,
consider such secondary prophylaxis a reasonable option,
aiming at reducing the risk of bacteraemia and potential
seeding of the LVAD.6
Vaccines are administrated like for every other HF patient,
and personal and household hygiene are encouraged.27
A good method for tracking the DL exit site wound is by
photography. In any suspected DL issues, a picture of the
DL exit site is encouraged to be shared with the LVAD team.
Reviewing the ‘photo album’ of previous pictures may help in
decision making. In places where due to medical confidential-
ity the use photographs are not permitted, comparing the pa-
tient’s DL exit site wound with a poster that shows different
levels of infection is advisable.
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DL infections: DL infections are classified into Superficial
DLI (SDLI) and Deep DLI (DDLI).
The SDLI is characterized by redness and tenderness of the
soft tissue surrounding the DL exit site occasionally with
some effusion. A swab culture even from the depths of the
wound should be taken and empiric (until the microbiological
results arrive) antibiotic therapy started. The preferred anti-
biotic therapy is combination of 1st generation cephalosporin
(for staphylococcal infection) and quinolone (for Pseudomo-
nas). Every centre is welcomed to change the antibiotic pro-
tocol according to the common pathogenic flora in that
region. The antibiotic therapy needs modification if the caus-
ative microbial agent has been identified. During DL or any
other infection, INR levels can be altered mandating frequent
INR monitoring. Following blood count and CRP levels is help-
ful. Frequent replacements of the DL dressings might also be
beneficial.
DDLI involves deeper tissues with purulent, sometimes
foul-smelling effusion from the DL exit site wound. The skin
above and along the subcutaneous cable tract is painful,
oedematous, and erythematous. Proximal progression of
the erythema above the DL indicates worsening uncontrolled
DDLI.
In DDLI, hospitalization is indicated for prompt empirical IV
antibiotic therapy (according to infectious diseases consult)
immediately after swab culture from the DL exit site effusion
and four blood culture samples obtained.
A peripherally inserted central catheter (PICC) facilitates
discharge home for long term antibiotic therapy ranging from
weeks, months and even longer.
Evaluation and follow-up of the DDLI includes ultrasono-
graphic and CT scanning to diagnose the depth and extent
of the DDLI and abscess formations along the subcutaneous
DL tract. PET CT is the most reliable imaging modality en-
abling accurate assessment of the therapeutic response. Daily
change of the dressing is mandated for assessment of the DL
exit site wound. When DDLI progresses despite optimal med-
ical therapy, surgical debridement of the wound is indicated.
Surgical opening of the cable origin to point where clean
non-infected tissue is identified the exit site is shifted to a
new exit site. The incision is mostly treated by
vacuum-assisted closure. When this surgery is unsuccessful
and the infectious process approaches or reaches the device
itself, pump replacement or emergent heart transplantation
are indicated.
• In any suspected external damage to the DL, contact the
LVAD team or the manufacturer.
• A fall or pull of the bag are the primary causes of infection.
• A good fixation of the DL can reduce the incidence of DL
infection.
• In any case of a bag fall, the healthcare provider must per-
form an assessment of the wound, consider starting an
empiric antibiotic, and consult the LVAD specialist.
• When empiric start of antibiotic therapy, treat the com-
mon pathogens as recommended by the nearest LVAD
centre.
Exercise training in patients with
ventricular assist devices
Exercise training (ET) is highly recommended in HF.74–77 More
recently, it has been proposed also in LVAD recipients,78,79
but with a non-homogeneous implementation, as shown by
the European Exercise Training Survey.80 The limited imple-
mentation is attributed to lack of knowledge, prioritization,
official recommendations, or heterogeneity of the surgical in-
tervention (simple or shared device implantation, combined
valve surgery, linked with ventricular ablation), indication,
or simply because of too severely frail individuals (such as
very elderly HF patients).
Based on the current consistent but still limited evidence
supporting the safety and the benefit of early mobilization
(EM) and ET in the LVAD population, the Heart Failure Asso-
ciation (HFA) of the European Society of Cardiology has de-
veloped practical advice on the modality of exercise
implementation in LVAD patients.81
Early mobilization
In every patient, as well as in LVAD recipients, EM, defined as
initiating physical exercise within the early illness phase, is
the first step for initiation of exercise therapy, and it consti-
tutes the basic standard modality for ET implementation, dur-
ing the post-acute phase. EM has to be considered82–84 when
patient’s haemodynamic state is stable (including surgical
wound, skin integrity maintenance, and pulmonary hygiene),
and LVAD functioning and troubleshooting have been cor-
rectly addressed. Regarding the timing of starting ET, the lim-
ited data available support the safety of 6 weeks interval
after the LVAD implantation.85,86 An algorithm for EM for
LVAD-supported patients and the transition to ET is here pro-
posed, based on expert opinion, and patient’s attitudes/clin-
ical state (Figure 1).
Exercise training
No guidelines describing the specific ET setting, modality, and
duration for LVAD-supported patients are available, but, only
limited evidence on implementation of light exercise intensi-
ties. Monitoring of exercise sessions is crucial, at least ini-
tially, which include the supervision of the patient, the
clinical adaptation, and the VAD functioning. To optimize
the exercise or the work-load prescription, a
symptom-limited cardiopulmonary exercise testing or 6 min
walking test (6MWT) according to local availability, is advis-
able, in order to aim at a peak workload below the
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predetermined ventilatory anaerobic threshold. If peak VO2 is
>14 mL/kg/min or 6MWT > 300 m, a more intensive ET can
be applied.
• Early mobilization post-VAD implantation, with safety of
6 weeks interval after the implantation is beneficial.
• 6 weeks period of changing intervals is recommended.
• To optimize the exercise or the work-load prescription, a
symptom-limited cardiopulmonary exercise testing (or
6MWT according to local availability) is advisable.
Pre-discharge recommendations:
Education and social support
Education and support of the LVAD-supported patient and
their close caregiver is vital during the different phases of
the LVAD-journey/trajectory. Communication between the
healthcare provider and the LVAD-supported patients, their
family, and caregivers need to be open and address the prac-
tical, psychological, and social consequences of the LVAD
implantation.
Education about living with a chronic disease has already
started during the HF trajectory and should continue and
shift focus during the process of evaluation for LVAD, deci-
sion making and consent, preparation, and post-device
implantation. Successful long-term LVAD support includes a
high degree of self-care by the patient and their caregiver
requiring long-term support from a multi-disciplinary
team.87 Self-care is defined as process of maintaining health
through health promoting practices and illness
management.88 All three components of self-care deserve
special attention once an HF patient has been supported
with an LVAD, including activities regarding self-care mainte-
nance (related both to the device and lifestyle), self-care
monitoring (e.g. monitoring for complications or distress),
and self-care management (e.g. handling alarms or coping
with living with the device).
Clinicians need to be aware of available materials in their
countries that can be used for education, decision making,
and support. In some countries, a broad spectrum of re-
sources exists for patients considered for LVAD implantation
or living with an LVAD, such as brochures, apps, and websites.
Some centres have their own education material, while
others use materials produced by the manufacturer. A recent
review described that information material might be subopti-
mal with strong emphasis on benefits of living with the LVAD
and lack of information on the potential risks, alternative op-
tions, and caregiver considerations. Most materials use out-
dated statistics, are above the reading level of average
patients, and are biased towards favouring the LVAD therapy.
It is therefore advised to scrutinize material that is used in
the education and care for LVAD patients.
Figure 1 Self care if LVAD supported patient: Maintenance, Monitoring and Management.
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Finally, optimal education of the LVAD patients and their
caregiver which focuses on knowledge and skills through a
collaborative, adult learning approach is needed. Not only
factual knowledge needs to be addressed (e.g. what is the
DL) but also separate learning strategies should be used
to develop skills and to apply knowledge in new situations
(e.g., what to do in case of new symptoms).
• The LVAD-supported patients have to be approached by a
multi-disciplinary team that will address the practical, psy-
chological, and social consequences of the LVAD
implantation.
• The patient and his caregiver need to have knowledge
about self-care maintenance, monitoring, and manage-
ment for best outcomes.
Palliative care and end-of-life issues in LVAD-
supported patients
The integration of a palliative approach into advanced HF
management has been recommended both within interna-
tional guidelines74,89 and expert position papers.90-93
Through improved therapeutic communication and discus-
sion of goals and preferences, informed decisions can be
made by the HF team, patient, and family regarding future
treatment options. However, most of the evidence regarding
palliative interventions for patients with LVADs remains di-
rected at those whereby the device was implanted for desti-
nation therapy (DT).
In a retrospective case-note review of all patients (n = 51)
awaiting LVAD implantation94 over a 20 month period, 28 pa-
tients received a palliative care consultation prior to implanta-
tion. Results showed that the consultation did not affect LVAD
placement, with seven patients (25%) requiring palliative care
follow-up. Controversially, authors concluded that although
this consultation was beneficial in the management of multi-
ple symptoms, ongoing follow-up was not always necessary.
Clinical trials such as REMATCH have demonstrated the
positive benefits of the LVAD95; however, for some patients,
expectations of the life post-LVAD do not equate to reality.
Furthermore, a recent study by the Mayo Clinic found that
the median time from implantation to death for patients with
a DT was 14 months96 with most patients dying in hospital
and only 46% receiving palliative care 1 month before death.
This is not surprising given the use of hospice provision by HF
patients in general, as well as considering post-implantation
complications and that many non-LVAD specialists remain un-
familiar with the advanced technology.
The RCTs have shown a collaborative palliative and HF ap-
proach to be beneficial.97,98 In the SWAP-HF study,99 patients
with LVAD who received the palliative intervention were
more likely to have a documented advance plan, indicating
they had an opportunity to discuss and have choice at the
end of life. Interestingly the study also found the intervention
did not affect anxiety, depression, or quality of life scores.
Similar to previous ICD studies on deactivation,100 many
professionals are reluctant to engage in discussions regarding
LVAD deactivation, perceiving the device as ‘life-saving’.
There was consensus that only when the patient was immi-
nently dying would the device be deactivated,101 with 13%
of cardiologists believing LVAD deactivation was a form of eu-
thanasia or physician-assisted suicide.
Improved collaborative approach between palliative and
HF both prior to and following LVAD implantation, irrelevant
of the indication, will inform realistic goals and expectations
by the patient and family. More research is required into
the provision of quality end of life care for this cohort of pa-
tients, exploring the needs of the patient and family mem-
bers. Finally, practical resources need to be considered that
can be tailored to meet the LVAD-supported patient’s needs,
as well as raising awareness of the need to educate profes-
sionals in the management of LVAD-supported patients.
• Palliative care is beneficial if started prior to the LVAD
implantation.
• Discuss realistic goals and expectations about LVAD im-
plantation as well as end of life decisions.
• A documented advance plan of deactivation of the LVAD
might prove helpful when needed.
End of part 3.
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